Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis LIVER INTERNATIONAL Kamal, S. M., Ahmed, A., Mahmoud, S., Nabegh, L., El Gohary, I., Obadan, I., Hafez, T., Ghoraba, D., Aziz, A. A., Metaoei, M. 2011; 31 (3): 401-411


The therapy of chronic hepatitis C genotype 4 (HCV-4) has not been optimized yet. This randomized, prospective, parallel-group clinical trial compared the efficacy and safety of pegylated interferon a-2a (PEG-IFN a-2a) plus ribavirin and PEG-IFN a-2b plus ribavirin and assessed the health-related quality of life (HRQOL) in patients with chronic HCV-4.Eligible patients with proven chronic HCV-4 were randomized to receive either a weekly dose of PEG-IFN a-2a (180 µg) or PEG-IFN a-2b (1.5 µg/kg) and a daily dose of ribavirin (1000-1200 mg) for 48 weeks with 24 weeks post-treatment follow-up. The primary end point was sustained virological response (SVR) defined by undetectable HCV RNA 24 weeks after treatment. The Short form-36 Health Survey version 2 (SF-36v2) and the Chronic Liver Disease questionnaires (CLDQ) were assessed before, during and after therapy.The overall SVR rate of the entire cohort was 59.9%. The SVR rates were significantly higher in patients treated with PEG-IFN a-2a and ribavirin (Group A; n=109) compared with those treated with PEG-IFN a-2b and ribavirin (Group B; n=108, 70.6 vs. 54.6%, respectively; P=0.017). The relapse rates were 5.1% for PEG-IFN a-2a and 15.7% for PEG-IFN a-2b (P=0.0019). The SF-36v2 and CLDQ were low during therapy and improved significantly after therapy successful therapy.Pegylated interferon a-2a plus ribavirin was significantly more effective than PEG-IFN a-2b and ribavirin therapy in the treatment of chronic HCV-4 patients. The tolerability and adverse events were comparable between the two regimens. The HRQOL improved significantly after successful PEG-IFN a-2a plus ribavirin therapy.

View details for DOI 10.1111/j.1478-3231.2010.02435.x

View details for Web of Science ID 000286836900018

View details for PubMedID 21281434